



ESMO Preceptorship on Hereditary Cancer Genetics

PROGRAMME

ESMO PRECEPTORSHIP

PARIS FRANCE
29-30 SEPTEMBER 2023

Co-Chairs

Judith Balmaña, Spain

Nicoline Hoogerbrugge, Netherlands

ESMO PRECEPTORSHIP PROGRAMME HEREDITARY CANCER GENETICS

Multidisciplinary management, standards of care
and future perspectives

Paris, France
29-30 September 2023

CO-CHAIRS

Judith Balmaña, Spain
Nicoline Hoogerbrugge, Netherlands

SPEAKERS

Stefan Aretz, Germany
Matteo Lambertini, Italy
Marjolijn Ligtenberg, Netherlands
Carla Oliveira, Portugal
Rolf Sijmons, Netherlands
Marc Tischkowitz, United Kingdom

LEARNING OBJECTIVES

- To learn about the best clinical practice in the multidisciplinary management of hereditary cancer syndromes
- To understand the molecular basis and heterogeneity of the genetic susceptibility to develop cancer
- To learn how to recognize, diagnose, treat and provide prevention recommendations to patients with a germline genetic susceptibility

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 29 September 2023

09:00-09:10 10'	Welcome and introduction	Judith Balmaña, ES Nicoline Hoogerbrugge, NL
09:10-10:50 100'	SESSION 1 Challenges in hereditary cancer in 2023	Chair: Judith Balmaña, ES
30'	Overview of the clinical challenges in hereditary cancer: Identification, treatment and prevention. The role of ERN-GENTURIS network in Europe	Nicoline Hoogerbrugge, NL
30'	Challenges of tumour sequencing, exome sequencing and liquid biopsies: Interpretation of pathogenicity, incidental findings, ruling out a germline origin	Marjolijn Ligtenberg, NL
30'	Challenges of risk communication in hereditary cancer	Rolf Sijmons, NL
10'	Q&A	All
10:50-11:20	Coffee break	
11:20-13:00 100'	SESSION 2 Hereditary gastrointestinal cancer	Chair: Nicoline Hoogerbrugge, NL
30'	Hereditary gastric cancer	Carla Oliveira, PT
30'	What an oncologist needs to know about polyposis and colorectal cancer germline susceptibility	Stefan Aretz, DE
30'	How to identify Lynch syndrome patients when treating patients with CRC	Judith Balmaña, ES
10'	Q&A	All
13:00-14:00	Lunch	
14:00-15:55 115'	SESSION 3 Hereditary prostate and pancreatic cancer: What an oncologist needs to know	Chair: Nicoline Hoogerbrugge, NL
30'	Germline susceptibility to prostate cancer: What genes to test, when, and why?	Rolf Sijmons, NL
30'	Advances in hereditary pancreatic cancer	Marc Tischkowitz, UK
10'	Q&A	All
45'	Participants clinical case discussion (3x15')	Faculty
15:55-16:25	Coffee break	
16:25-18:05 100'	SESSION 4 Challenges in identification of hereditary susceptibility	Chair: Judith Balmaña, ES
30'	Recognizing variants of germline origin in tumor sequencing: ESMO guidelines	Marjolijn Ligtenberg, NL
30'	PTEN-hamartoma syndrome	Nicoline Hoogerbrugge, NL
10'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
19:30	Dinner	

Saturday, 30 September 2023

09:00-10:30 90'	SESSION 5 Hereditary breast and ovarian cancer	Chair: Nicoline Hoogerbrugge, NL
25'	Germline susceptibility to breast and ovarian cancer in 2023	Marc Tischkowitz, UK
25'	How to adapt our clinics to deliver targeted therapies for hereditary breast and ovarian cancer	Judith Balmaña, ES
25'	The role of germline alterations in fertility and reproductive decision making	Matteo Lambertini, IT
15'	Q&A	All
10:30-11:00	Coffee break	
11:00-12:00 60'	SESSION 6 Participants clinical case discussion	Chairs: Judith Balmaña, ES Nicoline Hoogerbrugge, NL
60'	Participants clinical case discussion (4x15')	Faculty
12:00-12:15 15'	Conclusion and farewell	Judith Balmaña, ES Nicoline Hoogerbrugge, NL
12:15-13:15	Lunch	

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion